Serum carnitine levels in childhood leukemia

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 2, 2010, Pages e61-e69

  Rogalidou, Maria ^a   Evangeliou, Athanasios ^b   Stiakaki, Eftichia ^c   Giahnakis, Emmanouel ^a   Kalmanti, Maria ^a,b  

^a UNIVERSITY OF CRETE   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Carnitine; Chemotherapy; Children; Leukemia

Indexed keywords

CARNITINE; HEMOGLOBIN;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROSPRAY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; INTENSIVE CARE; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TANDEM MASS SPECTROMETRY;

ACUTE DISEASE; ADOLESCENT; BODY MASS INDEX; CARNITINE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LEUKEMIA; MALE; MUSCLE, SKELETAL;

EID: 77949441219     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181ca9eb9     Document Type: Article

References (57)

1. Yaris N, Akyuz C, Coskun T, et al. Serum carnitine levels of pediatric cancer patients. Pediatr Hematol Oncol. 2002;19: 1-8.
2. Peluso G, Nicolai R, Reda E, et al. Cancer and anticancer therapy-induced modifications on metabolism mediated by carnitine system. J Cell Physiol. 2000;182: 339-350.
3. Mc Garry JD, Brown NF. The mitochondrial carnitinepalmitoyltranferase system. From concept to molecular analysis. Eur J Biochem. 1997;244: 1-14.
4. Ramsay RR, Gandour RD, Van Der Leij FR. Molecular enzymology of carnitine transfer and transport. Biochim Biophys Acta. 2001;1546: 21-43.
5. Jakobs BS, Wanders RJ. Fatty acid β-oxidation in peroxisomes and mitochondria: the first unequivocal evidence for the involvement of carnitine in shutting propionyl-CoA from peroxisomes to mitochondria. Biochem Biophys Res Commun. 1995;213: 1035-1041.
6. Verhoeven NM, Roe DS, Kok RM, et al. Phytanic acid & pristanic acid are oxidized by sequential peroxisomal and mitochondrial reactions in cultured fibroblasts. J Lipid Res. 1998;39: 66-74.
7. Carter AL, Abney TO, Lapp DF. Biosynthesis and metabolism of carnitine. J Child Neurol. 1995;10(suppl 2): S3-S7.
8. Bremer J. Carnitine-metabolism and functions. Physiol Rev. 1983;63: 1420-1480.
9. Duran M, Loof NE, Ketting D, et al. Secondary carnitine deficiency. J Clin Chem Clin Biochem. 1990;28: 359-363.
10. Vaz MF, Wanders RJA. Carnitine biosynthesis in mammals. Biochem J. 2002;361: 417-429.
11. Border JR, Burns GP, Rumph C, et al. Carnitine levels in severe infection and starvation: a possible key to the prolonged catabolic state. Surgery. 1970;68: 175-179.
12. Murakami R, Tanaka A, Nakamura H. The effect of starvation on brain carnitine concentration in neonatal rats. J Pediatr Gastroenterol Nutr. 1997;25: 385-387.
13. Stumpf DA, Parker D, Angelini C. Carnitine deficiency, organic acidemias and Reye’s syndrome. Neurology. 1985;35: 1041-1045.
14. Cyr D, Giguere R, Giguere Y, et al. Determination of urinary acylcarnitines: a complementary aid for the high-risk screening of several organic acidurias using a simple and reliable GC/MS-based method. Clin Biochem. 2000;33: 151-155.
15. Reddi AS, Moquete M, Keshav G, et al. Plasma carnitine levels in patients undergoing hemodialysis. Nephron. 1998;80: 87-88.
16. Thomas S, Fischer FP, Mettang T, et al. Effects of L-carnitine on leucocyte function and viability in hemodialysis patients: a double-blind randomized trial. Am J Kidney Dis. 1999;34: 678-687.
17. Tein I, Sloane AE, Donner EJ, et al. Fatty acid oxidation abnormalities in childhood-onset spinal muscular atrophy: primary or secondary defect(s)? Pediatr Neurol. 1995;12: 21-30.
18. Rubio JC, de Bustos F, Molina JA, et al. Cerebrospinal fluid carnitine levels in patients with Alzheimer’s disease. J Neurol Sci. 1998;155: 192-195.
19. Plochl E, Sperl W, Wermuth B, et al. Carnitine deficiency and carnitine therapy in a patient with a Rett syndrome. Klin Padiatr. 1996;208: 129-134.
20. Cederblad G, Hermansson G, Ludvigsson J. Plasma and urine carnitine in children with diabetes mellitus. Clin Chim Acta. 1982;125: 207-217. (D10).
21. Morabito E, Corsico N, Marzo A, et al. Serum and urine levels of levocarnitine family components in genetically diabetic rats. Arzneimittelforschung. 1994;44: 965-968.
22. Pregant P, Schernthaner G, Legenstein E, et al. Decreased plasma carnitine in type I diabetes mellitus. Klin Wochenschr. 1991;69: 511-516.
23. Evangeliou A, Vlassopoulos D. Carnitine metabolism and deficit--when supplementation is necessary? Curr Pharm Biotechnol. 2003;4: 211-219.
24. Vassiliadis S, Evangeliou A, Basta E, et al. The role of L-carnitine on a restricted number of myeloid leukaemia progenitor cells: generation of atypical cell types. Haematologia (Budap). 2002;32: 341-353.
25. Yazdanpanah M, Luo X, Lau R, et al. Cytotoxic aldehydes as possible markers for childhood cancer. Free Radic Biol Med. 1997;23: 870-878.
26. Smith DE, Stevens MCG, Booth IW. Malnutrition at diagnosis of malignancy in childhood common but mostly missed. Eur J Pediatr. 1991;150: 318-322.
27. Donalson SS, Wesley MN, De Wys W, et al. A study of the nutritional status of paediatric cancer patients. Am J Dis Child. 1981;135: 1107-1112.
28. Vreken P, Van Lint AEM, Bootsna AH, et al. Quantitative plasma acylcarnitine analysis using electrospray tandem mass spectrometry for the diagnosis of organic acidaemias and fatty acid oxidation defects. J Inherit Metab Dis. 1999;22: 302-306.
29. Mamoulakis D, Galanakis E, Dionyssopoulou E, et al. Carnitine deficiency in children and adolescents with type 1 diabetes. J Diabetes Complications. 2004;18: 271-274.
30. Rogalidou ME, Stiakaki E, Evangeliou A, et al. Childhood malignant diseases: which is the carnitine’s role? J Pediatr Hematol Oncol. 2007;29: 291-292.
31. Delaney CE, Hopkins SP, Addison CL. Supplementation with L carnitine does not reduce the efficacy of epirubicin treatment in breast cancer cells. Cancer Lett. 2007;252: 195-207.
32. Rebouche CJ. Carnitine function and requirements during the life cycle. FASEB J. 1992;6: 3379-3386.
33. Rebouche CJ, Lombard KA, Chenad CA. Renal adaptation to dietary carnitine in humans. Am J Clin Nutr. 1993;58: 660-665.
34. Heuberger W, Berardi S, Jacky E, et al. Increased urinary expression of carnitine in patients treated with cisplatin. Eur J Clin Pharmacol. 1998;54: 503-508.
35. Neri S, Pistone G, Saraceno B, et al. L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis. C. Neuropsychobiology. 2003;47: 94-97.
36. Malaguarnera M, Di Mauro A, Gargante PM, et al. L carnitine reduces severity of physical and mental fatigue and improves daily activities in the elderly. South Med J. 2006;99: 315-316.
37. Kooistra MP, Struyvenberg A, Van Es A. The response to recombinant human erythropoietin in patients with anemia of end stage renal disease is correlated with serum carnitine levels. Nephron. 1991;57: 127-128.
38. Golper TA, Goral S, Becker BN, et al. L carnitine treatment of anemia. Am J Kidney Dis. 2003;41: S27-S34.
39. Lee MG, Pedersen PL. Glucose metabolism in cancer: importance of transcription factor-DNA interactions within a short segment of the proximal region of the type II hexokinase promoter. J Biol Chem. 2003;278: 41047-41058.
40. Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem. 2002;277: 23111-23115.
41. Zhou W, Mukherjee P, Kiebish MA, et al. The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr Metab (Lond). 2007;4: 5.
42. Seyfried TN, Mukherjee P. Targeting energy metabolism in brain cancer: review and hypothesis. Nutr Metab (Lond). 2005;2: 30.
43. Nicula P, Ruohola H, Alhonen-Hongisto L, et al. Carnitine prevents the early mitochondrial damage induced by methylglyoxal bis (guanylhydrazone) in L1210 leukemia cells. Biochem J. 1985;228: 513-516.
44. Cruciani RA, Dvorkin E, Homel P, et al. Safety tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer fatigue and carnitine deficiency: a phase I/II study. J Pain Symptom Manage. 2006;32: 551-559.
45. Cruciani RA, Dvorkin E, Homel P, et al. L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled-study. J Pain Symptom Manage. 2009;37: 622-631.
46. Graziano F, Bisonni R, Catalano V, et al. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. Br J Cancer. 2002;86: 1854-1857.
47. Stephens FB, Constantin-Teodosiu D, Greenhaff PL. New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. J Physiol. 2007;581(Pt 2): 431-444.
48. Rssle C, Pichard C, Roulet M, et al. Muscle carnitine pools in cancer patients. Clin Nutr. 1989;8: 341-346.
49. Arenas J, Ricoy JR, Encinas AR, et al. Carnitine in muscle, serum, and urine of nonprofessional athletes: effects of physical exercise, training, and L-carnitine administration. Muscle Nerve. 1991;14: 598-604.
50. De la Morena E, Berlanas EJ, Gomez C. Levo-carnitine, its derivatives, and free fatty acids in serum, heart, liver, and muscle of both tumoral and alcoholic rats. Clin Ther. 1988;10: 672-677.
51. Opalka JR, Gellerich FN, Zierz S. Age and sex dependency of carnitine concentration in human serum and skeletal muscle. Clin Chem. 2001;47: 2150-2153.
52. Anil M, Helvaci M, Ozbal E, et al. Serum and muscle carnitine levels in epileptic children receiving sodium valproate. J Child Neurol. 2009;24: 80-86.
53. Wachter S, Vogt M, Kreis R, et al. Long-term administration of L-carnitine to humans: effect on skeletal muscle carnitine content and physical performance. Clin Chim Acta. 2002;318: 51-61.
54. DiMauro S, Scott C, Penn AS, et al. Serum carnitine. An index of muscle destruction in man. Arch Neurol. 1973;28: 186-190.
55. Bellinghieri G, Savica V, Mallamace A, et al. Correlation between increased serum and tissue L-carnitine levels and improved muscle symptoms in hemodialyzed patients. Am J Clin Nutr. 1983;38: 523-531.
56. Ness KK, Baker KS, Dengel DR, et al. Body composition, muscle strength deficits and mobility limitations in adult survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2007;49: 975-981.
57. Brichard B, Vermylen C, Gosseye S, et al. Smooth muscle tumor developing in an immunocompromised child after therapy for leukemia. J Pediatr Hematol Oncol. 2001;23: 139-141.